Charles River, Roche add 3 years to drug discovery partnership

Charles River Labs

More than 10 years into their drug discovery alliance, Charles River Laboratories ($CRL) and Roche have decided to extend that collaboration for an additional three years.

The CRO said in a release that it will continue to help Genentech--Roche's ($RHHBY) biologics arm--identify promising candidates that have the potential of becoming innovative treatments by offering its drug discovery services, including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design.

Just two weeks ago, Charles River acquired Worcester, MA-based CRO Agilux, whose integrated discovery capabilities are complementary to Charles River’s existing early-stage research portfolio.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

That M&A is one of three the CRO initiated this year. Blue Stream, a Woburn, MA-based CRO known for its expertise in structural and functional protein characterization--a key element for development of biologics and biosimilars--was acquired by Charles River in June; and in April, the company completed purchase of WIL Research in a $585 million deal.

Taking in other CROs is not the only tactic Charles River adopted recently; after all, attracting new partners and clients should be any CRO’s goal, and Charles River clearly has a great appetite in that sense.

Besides the extension of the alliance with Genentech, it had recently entered into a new deal with U.K.-based Milner Therapeutics Institute and Consortium made up of biopharma giants like AstraZeneca ($AZN) and GlaxoSmithKline ($GSK) and academic institutes like the University of Cambridge to accelerate early-stage drug development processes. In June, it inked a deal with Moderna Therapeutics to assist in the latter’s novel mRNA treatments.

Charles River was down 1.1% at the end of play Wednesday, with a market cap of just over $3.7 billion. 

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.